Drug Profile

Camptothecin/podophyllotoxin - Neovia

Alternative Names: Neo 801; NEV-801

Latest Information Update: 25 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Neovia Oncology
Class Antineoplastics; Camptothecins; Small molecules
Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

25 Aug 2023 Camptothecin/podophyllotoxin is still in phase I trials for Cancer in USA (IV) (Neovia Oncology pipeline, Auugust 2023)
28 Feb 2020 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (IV)
30 Mar 2017 Chemical structure information added

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com